Genetic Signatures

Genetic Signatures FCF/Net Income

The Free Cash Flow to Net Income Ratio of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is 62.96 %. In the previous year, Free Cash Flow to Net Income Ratio was 65.61 % — a change of -4.05% (lower).

FCF/Net Income

62.96 %

YoY

-4.05%

Last updated:

Free Cash Flow to Net Income Ratio of Genetic Signatures is 2026 62.96 % . Free Cash Flow to Net Income Ratio of Genetic Signatures was 2025 65.61 % . It decreases by -4.05% lower compared to the previous year.

The Genetic Signatures FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2019
82.45 AUD
Jan 1, 2020
567.79 AUD
Jan 1, 2021
-44.65 AUD
Jan 1, 2022
222.56 AUD
Jan 1, 2023
146.21 AUD
Jan 1, 2024
83.48 AUD
Jan 1, 2025
65.61 AUD
Jan 1, 2026
62.96 AUD
The Genetic Signatures FCF/Net Income history
YEARFCF/Net IncomeYoY
62.96 %-4.05%
65.61 %-21.40%
83.48 %-42.90%
146.21 %-34.31%
222.56 %-598.49%
-44.65 %-107.86%
567.79 %+588.68%
82.45 %-36.32%
129.48 %-3.51%
134.18 %+37.97%
97.25 %-22.73%
125.86 %+25.35%
100.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Free Cash Flow to Net Income Ratio of Genetic Signatures is 62.96 % in 2026.

Free Cash Flow to Net Income Ratio of Genetic Signatures changed from 65.61 % to 62.96 %, representing a -4.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genetic Signatures

All Key Metrics — Genetic Signatures